Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. more
Time Frame | KRYS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.73% | -2.12% | -3% |
1-Month Return | -7.45% | -3.42% | -0.73% |
3-Month Return | -10.5% | -11.13% | 2.87% |
6-Month Return | -3.73% | -5.74% | 7.17% |
1-Year Return | 45.94% | 3.97% | 25.31% |
3-Year Return | 135.47% | 1.05% | 28.38% |
5-Year Return | 187.81% | 34.37% | 81.89% |
10-Year Return | 1449.15% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 50.70M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 974.00K | 1.85M | 2.77M | 4.05M | 3.09M | [{"date":"2019-12-31","value":24.02,"profit":true},{"date":"2020-12-31","value":45.65,"profit":true},{"date":"2021-12-31","value":68.29,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.3,"profit":true}] |
Gross Profit | (974.00K) | (1.85M) | (2.77M) | (4.05M) | 47.60M | [{"date":"2019-12-31","value":-2.05,"profit":false},{"date":"2020-12-31","value":-3.89,"profit":false},{"date":"2021-12-31","value":-5.82,"profit":false},{"date":"2022-12-31","value":-8.52,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | 93.90% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 22.08M | 33.00M | 68.28M | 120.20M | 157.33M | [{"date":"2019-12-31","value":14.03,"profit":true},{"date":"2020-12-31","value":20.97,"profit":true},{"date":"2021-12-31","value":43.4,"profit":true},{"date":"2022-12-31","value":76.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (22.08M) | (33.00M) | (68.28M) | (145.20M) | (109.73M) | [{"date":"2019-12-31","value":-2208100000,"profit":false},{"date":"2020-12-31","value":-3299900000,"profit":false},{"date":"2021-12-31","value":-6827500000,"profit":false},{"date":"2022-12-31","value":-14519600000,"profit":false},{"date":"2023-12-31","value":-10972700000,"profit":false}] |
Total Non-Operating Income/Expense | 5.99M | 1.66M | (2.59M) | 10.44M | 145.25M | [{"date":"2019-12-31","value":4.12,"profit":true},{"date":"2020-12-31","value":1.15,"profit":true},{"date":"2021-12-31","value":-1.78,"profit":false},{"date":"2022-12-31","value":7.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (19.09M) | (32.17M) | (69.57M) | (139.97M) | 12.90M | [{"date":"2019-12-31","value":-148,"profit":false},{"date":"2020-12-31","value":-249.41,"profit":false},{"date":"2021-12-31","value":-539.43,"profit":false},{"date":"2022-12-31","value":-1085.33,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | (2.99M) | 1.64M | 2.73M | 34.05M | 1.97M | [{"date":"2019-12-31","value":-8.79,"profit":false},{"date":"2020-12-31","value":4.83,"profit":true},{"date":"2021-12-31","value":8.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":5.77,"profit":true}] |
Income After Taxes | (16.09M) | (33.81M) | (72.30M) | (174.02M) | 10.93M | [{"date":"2019-12-31","value":-147.23,"profit":false},{"date":"2020-12-31","value":-309.29,"profit":false},{"date":"2021-12-31","value":-661.36,"profit":false},{"date":"2022-12-31","value":-1591.86,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (19.09M) | (33.00M) | (69.57M) | (139.97M) | 10.93M | [{"date":"2019-12-31","value":-174.61,"profit":false},{"date":"2020-12-31","value":-301.86,"profit":false},{"date":"2021-12-31","value":-636.39,"profit":false},{"date":"2022-12-31","value":-1280.42,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (19.09M) | (32.17M) | (69.57M) | (139.97M) | 10.93M | [{"date":"2019-12-31","value":-174.61,"profit":false},{"date":"2020-12-31","value":-294.25,"profit":false},{"date":"2021-12-31","value":-636.39,"profit":false},{"date":"2022-12-31","value":-1280.42,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | (1.22) | (1.70) | (3.06) | (4.51) | (3.40) | [{"date":"2019-12-31","value":-122,"profit":false},{"date":"2020-12-31","value":-170,"profit":false},{"date":"2021-12-31","value":-306,"profit":false},{"date":"2022-12-31","value":-451,"profit":false},{"date":"2023-12-31","value":-340,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
KRYS | |
---|---|
Cash Ratio | 6.57 |
Current Ratio | 7.97 |
Quick Ratio | 7.76 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KRYS | |
---|---|
ROA (LTM) | 4.58% |
ROE (LTM) | 6.38% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KRYS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KRYS | |
---|---|
Trailing PE | 89.85 |
Forward PE | 28.90 |
P/S (TTM) | 19.15 |
P/B | 5.22 |
Price/FCF | 80 |
EV/R | 16.75 |
EV/Ebitda | 22.34 |
Krystal Biotech Inc (KRYS) share price today is $164.83
Yes, Indians can buy shares of Krystal Biotech Inc (KRYS) on Vested. To buy Krystal Biotech Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KRYS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Krystal Biotech Inc (KRYS) via the Vested app. You can start investing in Krystal Biotech Inc (KRYS) with a minimum investment of $1.
You can invest in shares of Krystal Biotech Inc (KRYS) via Vested in three simple steps:
The 52-week high price of Krystal Biotech Inc (KRYS) is $219.34. The 52-week low price of Krystal Biotech Inc (KRYS) is $107.5.
The price-to-earnings (P/E) ratio of Krystal Biotech Inc (KRYS) is 87.5084
The price-to-book (P/B) ratio of Krystal Biotech Inc (KRYS) is 5.22
The dividend yield of Krystal Biotech Inc (KRYS) is 0.00%
The market capitalization of Krystal Biotech Inc (KRYS) is $4.51B
The stock symbol (or ticker) of Krystal Biotech Inc is KRYS